How was this Top 10 list ranked?

This list was ranked by the Top10Grid community through community voting. Rankings update in real-time as new votes come in.

What are the top 3 glp‑1 medications for weight loss & metabolic health (2026)?

The top 3 are: 1. Tirzepatide (Zepbound), 2. Semaglutide 2.4mg (Wegovy), 3. Semaglutide 7.2mg (Wegovy HD).

Haberdoedas Photography / Pexels

Compare

Top 10 GLP‑1 Medications for Weight Loss & Metabolic Health (2026)

Q: What is the #1 glp‑1 medications for weight loss & metabolic health (2026) on this list?

Tirzepatide (Zepbound) — Tirzepatide, marketed as Zepbound for obesity and Mounjaro for type 2 diabetes, is a first-in-class dual agonist that simultaneously activates both GL

Forget the old blockbusters—2026’s GLP-1 revolution is here, with triple agonists, affordable generics, and once-monthly shots. We cut through the hype to rank the top 10 medications proven to transform weight loss and metabolic health, analyzing head-to-head trial data and real-world outcomes. Whether you want to shed stubborn fat, balance blood sugar, or reduce cardiovascular risk, this guide reveals which therapy fits your goals—and which pitfalls to avoid.

Community-RankedUpdated Sep 7, 2026

The year 2026 marks an inflection point in the history of medicine. For the first time, clinicians can offer patients a portfolio of medications that reliably deliver 10 to 30 percent body weight reduction — results that rival bariatric surgery — without an operating room. GLP-1 receptor agonists, once obscure diabetes drugs whispered about in endocrinology journals, have become the most culturally significant pharmaceutical class in a generation. Ozempic is a household name. Zepbound and Wegovy are dinner-table topics. And now, an oral pill called Foundayo has removed the last remaining barrier for patients who feared needles. But the landscape in 2026 is no longer simple. There are ten meaningfully distinct options — approved, filing, or on the near-term horizon — each with a different mechanism, trial profile, price point, and patient type. Choosing the right GLP-1 is no longer a binary question of "should I take one?" It is a nuanced clinical and personal decision about which one, at what dose, with what support system, and at what cost. This guide cuts through the noise. We have analyzed every pivotal trial — SURMOUNT-1, STEP-1, SELECT, TRIUMPH-4, REDEFINE-1, ATTAIN — alongside real-world cost data, insurance formulary shifts, and the seismic Medicare GLP-1 Bridge program launching July 1, 2026. We rank all ten medications on six dimensions: weight loss efficacy, cost and insurance access, tolerability, administration convenience, cardiovascular and long-term evidence, and regulatory status. The science is clear on several fronts. Tirzepatide's dual GLP-1/GIP mechanism consistently outperforms semaglutide monotherapy in head-to-head trials, with SURMOUNT-5 showing a 6.5 percentage point advantage. The SELECT trial, enrolling 17,604 patients, proved that semaglutide's cardiovascular benefits operate independently of how much weight a patient loses — a paradigm shift that moves these drugs from cosmetic to cardiac medicine. And retatrutide, a triple-receptor agonist not yet approved, has produced 28.7 percent weight loss in Phase 3 — a number that would have seemed impossible five years ago. The access story is equally dramatic and more complicated. Two formulary decisions in early 2026 stripped coverage from 12 million Zepbound users and 12 million Wegovy users simultaneously. Compounded semaglutide, the affordable gray-market solution millions relied on, faces an FDA-proposed ban. Yet two new $149-per-month self-pay options — Foundayo and Wegovy HD — have emerged to fill the gap, and Medicare's bridge program will bring subsidized access to 3.4 million beneficiaries starting this July. The tolerability picture has matured too. A decade of post-market data has consistently shown that pancreatitis risk is no higher on GLP-1s than on placebo (pooled OR 0.99). Nausea remains the primary barrier, but slow titration protocols have reduced adverse-event discontinuation from 19 percent to just 2 percent in clinical practice. The 50 percent, 12-month discontinuation rate — and the known 0.4 kg per month weight regain after stopping — underscores that these are long-term therapies, not short-course fixes. What follows is the most comprehensive, data-grounded ranking of GLP-1 medications available in mid-2026. Whether you are a patient weighing your first prescription, a clinician updating your formulary knowledge, or a health-conscious reader trying to understand what your doctor is recommending, this guide gives you the full picture. The GLP-1 revolution is not coming. It is here. The only question is which option is right for you.

142 viewsMay 30, 2026 Updated Sep 7, 2026

Be the first

Compare by Dimension

Percentage of body weight lost in pivotal clinical trials at highest approved or tested dose

Rank	Item	Score	Notes
#1	Retatrutide (Investigational)	10.0	28.7% weight loss in TRIUMPH-4 — highest efficacy ever recorded for any weight-loss medication in clinical trials
#2	Tirzepatide (Zepbound)	9.0	20.9% weight loss in SURMOUNT-1 at 15mg; 20.2% in head-to-head SURMOUNT-5 — highest among approved medications
#3	CagriSema (Investigational)	9.0	22.7% in REDEFINE-1; 60% achieving ≥20% — second only to retatrutide among all agents in this ranking
#4	Semaglutide 7.2mg (Wegovy HD)	8.0	20.7% weight loss at 72 weeks — second highest among approved medications, near-equivalent to tirzepatide
#5	Semaglutide 2.4mg (Wegovy)	7.0	14.9% weight loss in STEP-1 at 68 weeks — strong but 6 points behind tirzepatide in head-to-head
#6	Orforglipron (Foundayo)	5.0	12.4% at 36mg in ATTAIN — meaningful efficacy but 8+ percentage points below tirzepatide and Wegovy HD
#7	Liraglutide (Saxenda)	3.0	~8% weight loss in SCALE — meaningful but roughly half the efficacy of semaglutide 2.4mg and a third of tirzepatide
#8	Dulaglutide (Trulicity)	2.0	3-4.7 kg weight loss in AWARD trials — the lowest efficacy of all GLP-1 agents in this ranking for weight management
#9	Semaglutide 3mg Oral (Rybelsus)	2.0	~3-5 kg weight loss in PIONEER trials at 14mg — not approved for obesity; among the lowest weight outcomes in this ranking
#10	Exenatide ER (Bydureon BCise)	1.0	~2-3 kg weight loss vs placebo — lowest weight reduction of all agents in this ranking

Current Rankings

0
#1
Tirzepatide (Zepbound)
Tirzepatide, marketed as Zepbound for obesity and Mounjaro for type 2 diabetes, is a first-in-class dual agonist that simultaneously activates both GLP-1 and GIP receptors. This dual mechanism amplifies satiety signaling beyond what GLP-1 alone can achieve, leading to calorie reduction that outpaces any single-receptor agent by over 32%, as shown by the 20.2% weight loss in SURMOUNT-5 versus Semaglutide 2.4mg (Wegovy)'s 13.7% — a 6.5 percentage point gap that is clinically enormous. FDA approved for chronic weight management in November 2023, landmark data from the SURMOUNT-1 trial at 15mg showed a mean 20.9% weight loss versus placebo's 3.1% over 72 weeks. A network meta-analysis gave tirzepatide the highest SUCRA score of 91.2 among GLP-1 class drugs. Dosing starts at 2.5mg weekly, titrating over 20 weeks to 10mg or 15mg via auto-injector with no food restrictions. Through Lilly Direct, self-pay price runs $299 to $449 monthly, down from $1,023 to $1,349 list. 2026 formulary changes dropped Zepbound from CVS Caremark, but Medicare's Bridge program from July 1, 2026 reopens coverage at ~$50 monthly for 3.4 million beneficiaries. Ideal for patients with BMI ≥30, or ≥27 with comorbidity, prioritizing maximum efficacy.
More info →
Details →
0
#2
Semaglutide 2.4mg (Wegovy)
Semaglutide 2.4mg (Wegovy) is the most comprehensively studied obesity medication in history, with over 17,604 adults in the SELECT trial alone — more than twice the largest tirzepatide study. A selective GLP-1 receptor agonist, it mimics the hormone released after meals to reduce appetite, slow gastric emptying, and modulate reward pathways. FDA approved for chronic weight management in June 2021, Wegovy launched the modern GLP-1 era. The STEP-1 trial showed 14.9% weight loss versus placebo's 2.4% at 68 weeks. The SELECT trial elevated Wegovy to a cardiovascular medicine: a 20% reduction in MACE (HR 0.80), heart failure hospitalization (HR 0.82), and all-cause mortality (HR 0.81) — benefits largely independent of weight loss. Dosing from 0.25mg weekly escalates over 16 weeks to 2.4mg. List price $1,200-$1,349 monthly, offset by NovoCare savings to $199-$349 self-pay. Medicare Bridge begins July 2026. Best for patients with both obesity and established cardiovascular disease.
More info →
Details →
0
#3
Semaglutide 7.2mg (Wegovy HD)
Semaglutide 7.2mg (Wegovy HD), FDA approved in April 2026, is Novo Nordisk's strategic answer to Tirzepatide (Zepbound)'s efficacy — delivering 20.7% mean weight loss at 72 weeks, nearly matching the 20.9% of tirzepatide and well above standard Wegovy's 14.9% ceiling. By tripling the dose of the same semaglutide molecule proven in the SELECT trial, it retains the cardiovascular protection profile (20% MACE reduction at 2.4mg) while closing the efficacy gap to within 0.2 percentage points. Administered once-weekly via a modified high-dose pen with gradual titration. Notably, introductory pricing through August 2026 is $149 monthly self-pay — matching Orforglipron (Foundayo)'s oral pill price and making it the highest-efficacy injectable at that price. Post-August 2026 pricing may change. GI side effects align with known semaglutide tolerability. Ideal for patients on standard Wegovy who plateaued and want to step up within the same molecule.
More info →
Details →
0
#4
Orforglipron (Foundayo)
Orforglipron (Foundayo) is the most structurally innovative GLP-1 therapy to reach the US market in a decade — a small-molecule non-peptide GLP-1 receptor agonist that is chemically stable and fully absorbed with or without food, unlike semaglutide's oral Rybelsus which requires a narrow fasting window. FDA approved April 1, 2026, it is taken once daily as a standard tablet, eliminating all injection logistics: no refrigeration, sharps disposal, needle anxiety, or injection-site issues. In the ATTAIN trial, the 36mg dose delivered 12.4% weight loss — 33% less than Tirzepatide (Zepbound)'s 20.2% in SURMOUNT-5 — but for an estimated 35% of obesity patients who refuse injectables, this oral efficacy is transformative. Lilly launched it at $149 monthly self-pay, with Medicare Bridge coverage at ~$50 copay from July 1, 2026. Side effects include GLP-1-typical GI symptoms, possibly attenuated by steady oral absorption. Best for needle-averse patients, frequent travelers, or first-time GLP-1 users seeking simplicity.
More info →
Details →
0
#5
Retatrutide (Investigational)
Retatrutide is a triple GLP-1/GIP/glucagon receptor agonist that represents the leading edge of pharmacological obesity treatment. By simultaneously activating three distinct metabolic receptors — GLP-1 for satiety and insulin secretion, GIP for glucose regulation and fat storage, and glucagon for energy expenditure — retatrutide creates a broader and more powerful metabolic reset than any previously approved agent. Eli Lilly's TRIUMPH-4 Phase 3 trial, results released in December 2025, produced the most dramatic weight loss data ever recorded for a pharmacological intervention: a mean 28.7 percent body weight reduction, approaching outcomes historically associated with bariatric surgery. This number is extraordinary in context — tirzepatide's dual-agonism produced 20.9 percent, meaning the addition of glucagon receptor activation contributed an estimated 8 percentage points of additional weight loss. Lilly has announced NDA filing plans for Q4 2026, meaning US regulatory approval could come in late 2027 if the review proceeds on a standard timeline. The drug is not yet available by prescription anywhere in the world as of May 2026. While efficacy dominates the narrative, real-world tolerability at these efficacy levels must be carefully characterized — greater fat mobilization and more aggressive appetite suppression may amplify GI side effects, and longer-term effects on bone density, lean muscle mass, and rebound weight gain after discontinuation require study. No cardiovascular outcomes trial data is yet available for retatrutide. Despite these limitations, retatrutide belongs in any 2026 GLP-1 ranking because its Phase 3 data are finalized, its regulatory timeline is concrete, and patients and clinicians should understand what is coming within 12 to 18 months.
More info →
Details →
0
#6
CagriSema (Investigational)
CagriSema is Novo Nordisk's answer to tirzepatide's dual-agonism: a fixed-dose combination of semaglutide (the proven GLP-1 agonist from Wegovy) and cagrilintide, a novel amylin receptor agonist. Amylin is a pancreatic hormone co-secreted with insulin that signals satiety through the brain's area postrema, slowing gastric emptying and reducing meal size through pathways distinct from GLP-1. By combining two complementary satiety mechanisms — GLP-1 and amylin — CagriSema aims to achieve additive appetite suppression without requiring glucagon receptor activation. The REDEFINE-1 Phase 3 trial produced a 22.7 percent mean weight loss, with a remarkable 60 percent of participants achieving 20 percent or greater body weight reduction — a threshold that historically required bariatric surgery. Novo Nordisk filed with the FDA in December 2025, placing potential US approval on a timeline of late 2026 to mid-2027 depending on review speed and any additional data requests. The combination of semaglutide's proven cardiovascular profile from SELECT with the additive amylin mechanism makes CagriSema one of the more compelling pipeline agents: it is not merely incremental but represents a meaningfully different physiological approach. The semaglutide component should inherit some cardiovascular benefit signals from existing SELECT data, though CagriSema-specific CV outcomes will require its own trial. Weekly subcutaneous injection is expected to be the delivery method, consistent with semaglutide's established pen infrastructure. Pricing has not been announced, but Novo Nordisk's existing NovoCare programs suggest competitive patient assistance will be available. CagriSema is positioned to compete directly with tirzepatide at the top of the approved efficacy table once it clears regulatory review. It achieves 22.7% mean weight loss, outperforming tirzepatide's 20.9% by 1.8 percentage points, a 9% relative improvement.
More info →
Details →
0
#7
Liraglutide (Saxenda)
Liraglutide (Saxenda) holds a singular place in the history of obesity pharmacology: it was the first GLP-1 receptor agonist approved specifically for chronic weight management, receiving FDA clearance in December 2014 — nearly seven years before semaglutide's obesity approval and nearly nine years before tirzepatide. A daily subcutaneous injection, liraglutide works through GLP-1 receptor agonism to reduce appetite and slow gastric emptying, the same fundamental mechanism as all later agents in this class. The pivotal SCALE trials established its efficacy: approximately 8 percent body weight reduction versus 2 to 3 percent for placebo at 56 weeks, with 3-year long-term follow-up data providing what remains one of the longest clinical evidence bases in the class. Over a decade of real-world post-market use has produced an extensive safety database — particularly reassuring for the rare but serious concerns (pancreatitis, thyroid effects) that are common questions for all GLP-1 drugs. Liraglutide's 3-year SCALE data also showed durable weight maintenance with continued use, though weight returns after discontinuation similarly to other agents. The primary clinical limitation in 2026 is competitive: the newer once-weekly agents (semaglutide, tirzepatide) produce 14.9 to 20.9 percent weight loss versus liraglutide's approximately 8 percent, and require only one injection per week versus Saxenda's daily dosing. The daily injection burden is a meaningful adherence challenge. However, Saxenda remains relevant for patients who have previously tolerated it well, those whose insurance covers it but not newer agents, and patients who prefer a well-established drug with the longest real-world experience of any GLP-1 obesity medication. Cost has come down modestly with generic competition pending.
More info →
Details →
0
#8
Dulaglutide (Trulicity)
Dulaglutide (Trulicity) is a once-weekly GLP-1 receptor agonist primarily approved for type 2 diabetes management, where it has established a strong evidence base through the AWARD trial series. Its weight loss benefit — approximately 3 to 4.7 kg in clinical trials — is modest compared to the newer obesity-approved agents, but its exceptional tolerability profile sets it apart in a meaningful way for a specific patient population. Among all GLP-1 agents, dulaglutide has the lowest reported nausea rate at approximately 10 percent — a full 10 percentage points below semaglutide and 15 points below tirzepatide. For patients who are GLP-1 naive and anxious about the GI side effects that drive early discontinuation, starting with dulaglutide offers the best chance of establishing tolerance before potentially transitioning to a higher-efficacy agent. The AWARD trials demonstrated consistent glycemic control with reductions in HbA1c of 1.4 to 1.5 percentage points, and the REWIND cardiovascular outcomes trial showed significant reduction in MACE (HR 0.88) for patients with established CV disease or multiple risk factors — providing a meaningful cardiovascular evidence base. Dulaglutide is administered via an innovative single-use, fully automated prefilled auto-injector pen that conceals the needle completely, which reduces injection anxiety substantially for new GLP-1 users. Dosing is once weekly at 0.75mg or 1.5mg, with a 3mg and 4.5mg high-dose option approved for additional glycemic and weight benefit. While not FDA approved for obesity as a primary indication, its off-label use for weight management in patients with type 2 diabetes who are GLP-1 intolerant of other agents reflects its clinical niche. Insurance coverage is broad for diabetes indications.
More info →
Details →
0
#9
Exenatide ER (Bydureon BCise)
Exenatide extended-release (Bydureon BCise) holds the distinction of being the world's first once-weekly GLP-1 receptor agonist approved for clinical use, and it was this dosing convenience innovation — not exenatide twice-daily (Byetta) — that set the template for the entire once-weekly GLP-1 landscape that followed. AstraZeneca developed Bydureon BCise as an easy-to-use, single-dose auto-injector tray that delivers 2mg of exenatide weekly without needle assembly, improving on the original Bydureon powder reconstitution that many patients found cumbersome. As a GLP-1 receptor agonist, exenatide ER reduces HbA1c through glucose-dependent insulin stimulation, suppresses inappropriate glucagon secretion, and reduces appetite — but its weight loss outcomes in clinical trials have consistently been the weakest among once-weekly GLP-1 agents, at approximately 2 to 3 kg versus placebo — a loss 30% lower than semaglutide's average in similar trials. The EXSCEL cardiovascular outcomes trial (n=14,752) demonstrated non-inferiority for cardiovascular safety (HR 0.91, 95% CI 0.83-1.00) but did not demonstrate superiority, unlike semaglutide's SELECT trial. Nausea is reported in 31.7 percent of patients — the highest nausea rate in the class, outperforming liraglutide's 20% rate — and injection-site nodule formation is a distinctive adverse effect specific to the PLGA microsphere formulation. The Bydureon BCise auto-injector requires weekly shaking to resuspend the microspheres and cannot be frozen, adding handling complexity. In 2026, exenatide ER is primarily prescribed for patients with type 2 diabetes who are already stabilized on it, where switching costs (both financial and clinical) outweigh the incremental benefits of newer agents. New prescriptions for exenatide ER for weight management are rare given the dramatically superior alternatives now available — over 90% of new GLP-1 weight loss prescriptions go to semaglutide or tirzepatide. Despite these limitations, it remains in current prescribing for established T2D patients where continuity of care outweighs switching to a newer agent.
More info →
Details →
0
#10
Semaglutide 3mg Oral (Rybelsus)
Rybelsus (oral semaglutide 3mg, 7mg, 14mg) was a breakthrough achievement in pharmaceutical chemistry when it launched in 2019 — the first oral GLP-1 receptor agonist to successfully overcome the challenge of peptide degradation in the GI tract. Novo Nordisk accomplished this by co-formulating semaglutide with SNAC (sodium N-[8-(2-hydroxybenzoyl)amino]caprylate), an absorption enhancer that temporarily raises gastric pH and facilitates transcellular peptide transport across the stomach lining. However, this mechanism imposes strict dosing constraints that no other GLP-1 medication requires: the tablet must be taken on an empty stomach with no more than 4 ounces (120mL) of water, followed by 30 minutes of continued fasting before any food, drink, or other medications. Missing any of these requirements substantially reduces bioavailability and blunts efficacy. The PIONEER trial series established Rybelsus's clinical profile for type 2 diabetes: meaningful HbA1c reduction and modest weight loss, though the weight reduction at 14mg — approximately 3 to 5 kg — is modest compared to the injectable obesity agents. Importantly, Rybelsus is not FDA approved for obesity or weight management; it is approved only for type 2 diabetes, and its modest weight loss makes it inappropriate as a primary weight management tool in 2026. The commercial context has shifted dramatically with the April 2026 approval of orforglipron (Foundayo), an oral GLP-1 with no dietary restrictions, superior weight loss of 12.4 percent, and equal or lower pricing. For new patients seeking an oral GLP-1, Foundayo is now the preferred choice. Rybelsus retains value primarily for patients with type 2 diabetes who are already stabilized on it or who have specific insurance formulary constraints that favor it.
More info →
Details →